Skip to content

Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.

Vagal Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke Requiring Mechanical Thrombectomy.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05417009
Acronym
VANS
Enrollment
36
Registered
2022-06-14
Start date
2023-04-26
Completion date
2023-07-21
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Dysfunction, Autonomic Imbalance, Ischemic Stroke, Thrombotic Stroke

Brief summary

Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.

Detailed description

Loss of autonomic variability is strongly associated with adverse outcomes after ischaemic stroke. Removing blood clots from the brain by mechanical thrombectomy has revolutionised the management of stroke, but more than 50% of patients do not regain functional independence.(PMID:26898852) Blood pressure (BP) control is important, since low and high BP (BP variability) are strongly associated with poor patient outcomes after thrombectomy. (PMIDs:32961389;31964286) Autonomic dysfunction causes labile blood pressure. Intact autonomic function is required to control blood pressure and potentially improve recovery after stroke. Impairment of baroreflex autonomic function, due to reduced vagal activity is associated with extreme BP variability, leading to further brain injury and cardiovascular complications.(PMID:30371208) Reduced baroreflex control is related to poor patient outcomes after stroke, independent of absolute blood pressure.(PMID:19834010) Reversing baroreflex and vagal dysfunction is, therefore, widely held to have the potential to improve cardiovascular control and patient outcome in this context.(PMID:19834010) Non-invasive peripheral neuromodulation restores autonomic control. Vagal nerve stimulation improves autonomic control and reverses baroreflex dysfunction (PMIDs:28949064) but this has previously required surgically implanted devices which are expensive and impractical in the context of acute stroke. Afferent Electronic have achieved the same effect as these implantable devices by non-invasive transcutaneous autonomic neuromodulation (TAN). We have used this simple, safe, hand-held, low-cost device to increase vagal activity and baroreflex sensitivity through non-invasive, painless stimulation of nerves located in the outer ear to control blood pressure. Baroreflex sensitivity can be increased at the bedside by TAN for 30 minutes following acute trauma. If this can be replicated in thrombectomy patients, it will aid recovery and rehabilitation through five complementary mechanisms where it has been clinically demonstrated that increasing vagal nerve activity: 1. Restore baroreflex sensitivity; 2. Increase blood flow to ischaemic brain tissue through vagal activation.(PMID:27357059) 3. Dampen cerebral/systemic inflammation.(PMID:26723020); 4. Reduce atrial fibrillation and myocardial injury,(PMIDs:5744003,22739118) which are common after stroke, and independently predict cognitive decline and cardiovascular mortality 5. Allows immediate commencement of vagal nerve stimulation, which has recently been shown to enhance upper-limb rehabilitation.(PMID:33894832) Our proof-of-concept data shows daily TAN reduces BP and BP variability lasting several months even in drug-resistant hypertensive patients. In this proof-of-concept randomised sham-controlled trial, we will examine whether early TAN on presentation for mechanical thrombectomy improves autonomic function in patients with acute ischaemic stroke by reducing blood pressure lability.

Interventions

DEVICEtrans-cutaneous auricular sensory stimulation

Transcutaneous auricular sensory stimulation

Sponsors

Queen Mary University of London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Sham settings for neuromodulation device.

Intervention model description

RCT

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Undergoing mechanical thrombectomy for acute ischaemic stroke requiring general or sedation. * Established hypertensive and/or hypertensive on admission for mechanical thrombectomy \[systolic BP \>140mmHg; diastolic BP \>80mmHg\]

Exclusion criteria

* Current participation in a clinical trial of a treatment with a similar biological mechanism. * Previous enrolment into VANS trial. * Anatomical or other contraindication to trans-cutaneous auricular sensory stimulation * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Blood Pressure Variability0-24h after mechanical thrombectomyCoefficient of variation of systolic blood pressure

Secondary

MeasureTime frameDescription
Systolic Blood Pressure Variability.0-24h after mechanical thrombectomySystolic blood pressure standard deviation.
Diastolic Blood Pressure Variability24h after admission for mechanical thrombectomycoefficient of variation- diastolic blood pressure

Countries

United Kingdom

Participant flow

Recruitment details

Patients referred for urgent mechanical thrombectomy.

Participants by arm

ArmCount
Stimulation - n=18
Electrodes attached bilaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current. trans-cutaneous auricular sensory stimulation: Transcutaneous auricular sensory stimulation
18
Electrode Attachment Only - n=18
Electrodes attached bilaterally to tragus nerve region of outer ear, with device switched off \[blinded to operator\]. trans-cutaneous auricular sensory stimulation: Transcutaneous auricular sensory stimulation
18
Total36

Baseline characteristics

CharacteristicStimulation - n=18Electrode Attachment Only - n=18Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
11 Participants13 Participants24 Participants
Age, Categorical
Between 18 and 65 years
7 Participants5 Participants12 Participants
Age, Continuous69 years
STANDARD_DEVIATION 13
69 years
STANDARD_DEVIATION 15
69 years
STANDARD_DEVIATION 14
Race/Ethnicity, Customized
Non-white
8 Participants3 Participants11 Participants
Race/Ethnicity, Customized
Other
10 Participants15 Participants25 Participants
Region of Enrollment
United Kingdom
18 participants18 participants36 participants
Sex: Female, Male
Female
13 Participants9 Participants22 Participants
Sex: Female, Male
Male
5 Participants9 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 182 / 18
other
Total, other adverse events
2 / 180 / 18
serious
Total, serious adverse events
0 / 180 / 18

Outcome results

Primary

Blood Pressure Variability

Coefficient of variation of systolic blood pressure

Time frame: 0-24h after mechanical thrombectomy

ArmMeasureValue (MEAN)Dispersion
StimulationBlood Pressure Variability0.106 coefficient of variationStandard Deviation 0.029
Electrode Attachment Only.Blood Pressure Variability0.107 coefficient of variationStandard Deviation 0.027
Secondary

Diastolic Blood Pressure Variability

coefficient of variation- diastolic blood pressure

Time frame: 24h after admission for mechanical thrombectomy

ArmMeasureValue (MEAN)Dispersion
StimulationDiastolic Blood Pressure Variability0.136 coefficient of variationStandard Deviation 0.05
Electrode Attachment Only.Diastolic Blood Pressure Variability0.127 coefficient of variationStandard Deviation 0.04
Secondary

Systolic Blood Pressure Variability.

Systolic blood pressure standard deviation.

Time frame: 0-24h after mechanical thrombectomy

ArmMeasureValue (MEAN)Dispersion
StimulationSystolic Blood Pressure Variability.14 mmHgStandard Deviation 5
Electrode Attachment Only.Systolic Blood Pressure Variability.14 mmHgStandard Deviation 4

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026